Palvella Therapeutics (PVLA)
NASDAQ:PVLA
Total Valuation
Palvella Therapeutics has a market cap or net worth of $1.76B. The enterprise value is $1.40B.
Market Cap$1.76B
Enterprise Value$1.40B
Share Statistics
Palvella Therapeutics has 14,313,659 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding14,313,659
Owned by Insiders2.01%
Owned by Institutions43.73%
Financial Efficiency
Palvella Therapeutics’s return on equity (ROE) is -1.49 and return on invested capital (ROIC) is -79.73%.
Return on Equity (ROE)-1.49
Return on Assets (ROA)-0.70
Return on Invested Capital (ROIC)-79.73%
Return on Capital Employed (ROCE)-0.80
Revenue Per Employee0.00
Profits Per Employee-2.98M
Employee Count14
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Palvella Therapeutics is ―. Palvella Therapeutics’s PEG ratio is 0.54.
PE Ratio―
PS Ratio0.00
PB Ratio42.09
Price to Fair Value42.09
Price to FCF-47.10
Price to Operating Cash Flow-69.83
PEG Ratio0.54
Income Statement
In the last 12 months, Palvella Therapeutics had revenue of 0.00 and earned -41.72M in profits. Earnings per share was -3.71.
Revenue0.00
Gross Profit0.00
Operating Income-38.60M
Pretax Income-41.72M
Net Income-41.72M
EBITDA-35.90M
Earnings Per Share (EPS)-3.71
Cash Flow
In the last 12 months, operating cash flow was -19.34M and capital expenditures 0.00, giving a free cash flow of -19.34M billion.
Operating Cash Flow-19.34M
Free Cash Flow-19.34M
Free Cash Flow per Share-1.35
Dividends & Yields
Palvella Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.07
52-Week Price Change465.00%
50-Day Moving Average108.61
200-Day Moving Average77.07
Relative Strength Index (RSI)54.36
Average Volume (3m)363.89K
Important Dates
Palvella Therapeutics upcoming earnings date is May 14, 2026, TBA (Confirmed).
Last Earnings DateMar 31, 2026
Next Earnings DateMay 14, 2026
Ex-Dividend Date―
Financial Position
Palvella Therapeutics as a current ratio of 5.20, with Debt / Equity ratio of 2.26%
Current Ratio5.20
Quick Ratio5.20
Debt to Market Cap<0.01
Net Debt to EBITDA1.60
Interest Coverage Ratio-6.63
Taxes
In the past 12 months, Palvella Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Palvella Therapeutics EV to EBITDA ratio is -31.21, with an EV/FCF ratio of -44.80.
EV to Sales0.00
EV to EBITDA-31.21
EV to Free Cash Flow-44.80
EV to Operating Cash Flow-44.80
Balance Sheet
Palvella Therapeutics has $57.98M in cash and marketable securities with $633.00K in debt, giving a net cash position of $57.35M billion.
Cash & Marketable Securities$57.98M
Total Debt$633.00K
Net Cash$57.35M
Net Cash Per Share$4.01
Tangible Book Value Per Share$2.49
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Palvella Therapeutics is $232.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$232.50
Price Target Upside88.76% Upside
Analyst ConsensusStrong Buy
Analyst Count13
Revenue Growth Forecast―
EPS Growth Forecast―